Plain-English translation of NCT06594445 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new medication called GTB-3650 that works by waking up your natural killer cells — a type of immune cell — to attack cancer cells. The medication is designed for people with advanced blood cancers (specifically high-risk myelodysplastic syndrome or relapsed acute myeloid leukemia) who have limited other options. Researchers believe this treatment could help control the cancer by both targeting the cancer cells directly and reducing immune suppression caused by the disease.
Current treatment options don't work well enough for many people with these advanced blood cancers, especially those who cannot have a stem cell transplant. This medication represents a new approach using the body's own immune system to fight the cancer.
You likely qualify if…
You likely don't qualify if…
You would stay in the hospital for three consecutive 24-hour infusions of the medication, given through a continuous IV line — that's one treatment "block" lasting 72 hours. A full treatment cycle consists of two of these blocks, followed by about 18 days at home with no treatment. You could receive up to four treatment cycles total if the treatment is working and you remain eligible. Before each block starts, you'll have tests to make sure it's safe to continue, and you'll need to stay within 60 minutes of the hospital during the first cycle to be monitored for any side effects.
AI-generated summary from trial data · Jul 17, 2026 · Not medical advice
United States